Annexon Biosciences

Contributing Author

Recent Articles by Annexon Biosciences

Aug-27	Annexon Biosciences to Participate in Upcoming September Investor Conferences ANNX GlobeNewswire
Aug-18	Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) ANNX GlobeNewswire
Aug-14	Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones ANNX GlobeNewswire
Aug-07	Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy ANNX GlobeNewswire
Jul-24	Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy ANNX GlobeNewswire
Jun-18	Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA) ANNX GlobeNewswire
May-29	Annexon Biosciences to Present at the Jefferies Global Healthcare Conference ANNX GlobeNewswire
May-19	Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barre Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting ANNX GlobeNewswire
May-16	Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) ANNX GlobeNewswire
May-12	Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones ANNX GlobeNewswire
May-09	Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barre Syndrome (GBS) at the 2025 PNS Meeting ANNX GlobeNewswire
May-07	Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress ANNX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.